Matrigel Unboxed: The 3D Matrix Powering Breakthroughs from Cell Culture to Organoids

Matrigel, a basement-membrane matrix derived from the Engelbreth–Holm–Swarm (EHS) mouse sarcoma, is a multifunctional scaffold in modern biomedical research. Composed primarily of laminin-111 (~60 %), collagen IV (~30 %) and nidogen/entactin (~8 %), it is further supplemented with heparan-sulfate proteoglycans and a cocktail of growth factors (VEGF, TGF-β, EGF, IGF, FGF-2, PLAT). This composition allows rapid thermal gelation at 22–37 °C into a biologically active three-dimensional extracellular matrix (ECM) that closely recapitulates the architecture, biochemical composition and mechanical properties of the native basement membrane. From conventional 2-D culture to advanced organoid systems, cancer biology and high-throughput drug screening, Matrigel has permeated virtually every corner of contemporary life-science research.

01 What is Matrigel?

Matrigel—also referred to as basement-membrane extract (BME) or ECM gel—is a soluble preparation of basement-membrane proteins isolated from the Engelbreth–Holm–Swarm mouse sarcoma. Upon warming to 22–37 °C it polymerizes into a three-dimensional, biologically active hydrogel that mimics the structural, compositional and functional characteristics of the in vivo basement membrane.

Complex composition

The macromolecular assembly comprises ~60 % laminin-111, ~30 % collagen IV and ~8 % nidogen-1/entactin, providing tensile strength and cell-adhesion motifs. Nidogen serves as a bridging molecule, cross-linking laminin and collagen IV networks to stabilize the supramolecular architecture.

Additional components include perlecan (heparan-sulfate proteoglycan) and a spectrum of growth factors: vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), epidermal growth factor (EGF), insulin-like growth factor (IGF), basic fibroblast growth factor (FGF-2) and tissue plasminogen activator (PLAT).

Product diversification

To accommodate distinct experimental requirements, Matrigel is supplied in multiple formulations: standard, growth-factor-reduced (GFR), high-concentration (HC), high-concentration/GFR, stem-cell-qualified and organoid-qualified versions.

Protein concentrations vary accordingly: standard lots contain 8–13 mg ml⁻¹, whereas HC lots reach 16–26 mg ml⁻¹, enabling tunable stiffness and ligand density.

02 Broad applications

Cell migration and invasion assays

In metastasis research, Matrigel-coated Transwell inserts serve as an in vitro basement-membrane barrier. Tumour cells must activate invasive programs—secreting matrix metalloproteinases (MMPs) and responding to chemokine gradients—to traverse the 3-µm-pore polycarbonate membrane.

Protocol: dilute Matrigel 1:8 in serum-free medium, coat the upper surface of the insert (50 µl cm⁻²), polymerise at 37 °C for 30 min, seed serum-starved cells (1×10⁵ per insert), and allow invasion toward a chemoattractant for 12–48 h. Fix, stain (0.1 % crystal violet) and enumerate invaded cells.

Three-dimensional cell culture

Unlike rigid 2-D plastic, Matrigel provides a viscoelastic 3-D microenvironment that promotes physiologically relevant cell–cell and cell–ECM interactions, restoring apical–basal polarity and tissue-specific gene-expression profiles.

Thin-gel (0.5 mm) and thick-gel (1–2 mm) protocols are employed for adhesion-dependent proliferation versus bona-fide 3-D morphogenesis, respectively.

Cells cultured within Matrigel exhibit transcriptomic and signalling signatures that closely resemble those observed in vivo, offering a more predictive platform for disease modelling and drug validation.

Organoid culture

Organoids are self-organising 3-D structures derived from adult stem cells (ASCs) or pluripotent stem cells (PSCs) that recapitulate key architectural and functional features of native organs. Growth-factor-reduced, phenol-red-free Matrigel is routinely used to minimise exogenous signalling interference and optical background.

Examples include murine cholangiocyte and airway epithelial organoids, both of which require the integrin-binding motifs and stiffness provided by Matrigel for long-term expansion.

In vivo tumorigenicity assays

Subcutaneous co-injection of tumour cells with high-concentration Matrigel into immunodeficient mice accelerates engraftment and increases take-rate by providing an immediate pro-angiogenic and pro-survival niche prior to host vascularisation.

Empirical data show a ~4-fold increase in mean tumour mass relative to PBS controls when 1×10⁶ cells are suspended in 1:1 Matrigel:PBS and injected within 30 min of mixing.

Angiogenesis studies

Human umbilical-vein endothelial cells (HUVECs) plated on polymerised Matrigel undergo rapid tube formation (≤4 h), generating capillary-like networks that are quantifiable for total tube length, branching points and lumen area. The assay is widely used to screen pro- and anti-angiogenic compounds and to dissect VEGF–VEGFR2 downstream signalling cascades.

03 How to use

Thawing and aliquoting

Matrigel is stored at –20 °C. Thaw overnight at 4 °C on ice in the dark; high-protein lots may require ≥12 h. Gently swirl—do not vortex—to homogenise, then pre-chill pipette tips and aliquot into cryotubes on ice to avoid repeated freeze–thaw cycles.

Coating protocols

Three standard methods are employed:

• Thin-gel coating: 50 µl cm⁻², ~0.5 mm thick, 30 min at 37 °C for adhesion and proliferation assays.
• Thick-gel culture: 150–200 µl cm⁻² mixed with cells, 1–2 mm thick, for bona-fide 3-D culture.
• Thin-layer adsorption: dilute Matrigel in ice-cold PBS to 50–100 µg ml⁻¹, coat overnight at 4 °C, aspirate—no gel forms, useful for surface functionalisation.

Critical precautions

• Keep Matrigel on ice (≤10 °C) at all times; gelation begins at ≥10 °C.
• Aliquot once—avoid multiple freeze–thaw cycles that degrade protein structure and bioactivity.
• Discard any unused liquid Matrigel after an experiment; do not re-freeze.

04 How to choose

Match formulation to application

• Routine 2-D/3-D culture, angiogenesis and invasion assays → standard Matrigel.
• Signal-transduction or transcriptomic studies requiring minimal cytokine background → growth-factor-reduced (GFR) Matrigel.
• In vivo tumourigenicity or angiogenesis requiring high stiffness → high-concentration (HC) Matrigel.
• hESC or iPSC culture → stem-cell-qualified Matrigel (tested for pluripotency maintenance).
• Organoid derivation and long-term expansion → organoid-qualified, phenol-red-free, GFR Matrigel.

Key quality metrics

• Protein concentration: standard 8–13 mg ml⁻¹; HC 16–26 mg ml⁻¹.
• Endotoxin: ≤4–8 EU ml⁻¹ for in vivo applications.
• Safety: LDEV (lactate-dehydrogenase-elevating virus) negative.
• Lot-to-lot consistency: request CoA and functional validation (tube-formation or organoid efficiency).

Advances in biomaterials engineering and microphysiological systems continue to expand Matrigel applications into organ-on-a-chip, regenerative medicine and personalised therapy. As our understanding of the stem-cell niche deepens, next-generation matrices will likely combine defined synthetic polymers with tissue-specific decellularised ECM, further propelling life-science discovery.

Selecting the appropriate Matrigel formulation and rigorously adhering to handling protocols are essential for reproducible and biologically relevant results.

Absin Matrigel selection guide

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio